Compare AbbVie Inc (ABBV) vs Align Technology, Inc. (ALGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Align Technology, Inc. — how do they compare? AbbVie Inc trades at $248.68 (market cap $438.19B), while Align Technology, Inc. trades at $172.77 (market cap $12.51B). The key difference: AbbVie Inc is far larger — about 35× Align Technology, Inc.'s market cap, and AbbVie Inc pays a 2.79% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | ALGN | |
|---|---|---|
Market Cap | $438.19B | $12.51B |
Sector | Health | Health |
52-Week High | $263.58 | $197.51 |
52-Week Low | $197.38 | $124.88 |
Enterprise Value | $502.45B | $11.52B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
ALGN trades at $173.66, up 2.71% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $2.64 surpassing the $2.62 estimate. Revenue reached a record $1.06 billion in Q2 2026, driven by clear aligner growth. Recent board changes and strategic initiatives aim to enhance long-term value.
The outlook is positive, supported by robust fundamentals and institutional interest, but risks include competitive pressures and scanner segment weakness. Valuation multiples remain below historical peaks, offering potential upside if growth accelerates. Investor sentiment is cautiously optimistic amid ongoing operational reviews.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →
